LBRX vs MET · $803.4M cap vs P/E 13, rev $38.23B
LB Pharmaceuticals Inc Common Stock (LBRX) versus MetLife Inc (MET) — a side-by-side from cached financials, not a winner call.
LB Pharmaceuticals Inc Common Stock (LBRX) is a biotechnology company listed on NASDAQ.
MetLife Inc (MET) is a insurance - life company listed on US.
LBRX does not have a complete income-statement cache yet.
Latest reported MET revenue for 2026-06-30 was $38.23B. Net income was $1.92B. MET currently screens at market cap $52.16B and trailing P/E 12.7.
LBRX currently screens at market cap $803.4M. MET currently screens at market cap $52.16B and trailing P/E 12.7.
Not investment advice. Open the LBRX and MET stock pages for the full models.
Not investment advice.